Month: September 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: The phase-transfer catalysts (C1-C11) were synthesized according to the proceduresbelow. To a solution of cinchonidine (1.00 g, 3.4 mmol) in THF (50 mL) was addedthe aryl benzyl bromides (3.4 mmol). The mixture was heated for 6-8 h at reflux.After cooling to room temperature, the mixture was poured into MTBE (150 mL)under stirring. The precipitated solid was filtrated and recrystallized fromCH3OH/MTBE to afford C1-C11, 485-71-2

485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Li, Ruipeng; Liu, Zhenren; Chen, Liang; Pan, Jing; Zhou, Weicheng; Beilstein Journal of Organic Chemistry; vol. 14; (2018); p. 1421 – 1427;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3922-40-5, 1,10-Phenanthroline-4,7-diol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To the reaction flask by adding 4.2 g (0.02mol) 4,7-dihydroxy -1,10-phenanthroline, 3.4 g (0.02mol) copper chloride dihydrate, 20 ml anhydrous acetic acid, 5 ml water, heating reflux for 10 hours, still, to separate out the solid, the solid drying cocatalyst 4.0 g., 3922-40-5

3922-40-5 1,10-Phenanthroline-4,7-diol 77524, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Zhengzhou University; Li, RuiJun; Li, xueyang; Li, CaiJuan; Li, Jie; Yang, GuanYu; (8 pag.)CN104151133; (2016); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.,485-71-2

General procedure: A mixture of (-)-cinchonidine (1.0 mmol) and benzyl bromide 3 (1.0 mmol) having sulfonamidegroup was stirred in DMF (4 mL) at 25 C for 20 h. After the reaction was completed, the reaction mixture was added dropwise to ether (50mL) with stirring. The solid precipitated was filtered,washed with ether (20 mL) and hexane (20 mL) to afford cinchonidinium salt 5

The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Itsuno, Shinichi; Yamamoto, Shunya; Takata, Shohei; Tetrahedron Letters; vol. 55; 44; (2014); p. 6117 – 6120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1126-58-5, 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a magnetically stirred solution of substituted isatin (5mmol) in 7ml of absolute ethanol, a corresponding pyridinium acetohydrazide (5mmol) and three drops of trifluoroacetic acid were successively added. The reaction mixture was heated under reflux for 3h. After spontaneously cooling the solution to room temperature, the precipitate formed was filtered, washed with absolute ether and dried in vacuo.

1126-58-5, 1126-58-5 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride 70773, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Bogdanov, Andrei V.; Zaripova, Ilyuza F.; Voloshina, Alexandra D.; Sapunova, Anastasia S.; Kulik, Natalia V.; Tsivunina, Irina V.; Dobrynin, Alexey B.; Mironov, Vladimir F.; Journal of Fluorine Chemistry; vol. 227; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.56100-20-0,5-Methyl-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,56100-20-0

To a mixture of dry diisopropylamine (1.0 mL, 7.1 mmol) and dry THF (50 mL) was added dropwise n-butyllithium (1.6 M hexane solution, 3.8 mL, 6.1 mmol) at -78 C under a nitrogen atmosphere. The solution was stirred for 30 min and 6 (681 mg, 4.00 mmol) in dry THF (15 mL) was added at -78 C. The solution was stirred for 1 h and 1,4-dibromobutane (4.32 g, 20.0mmol) in dry THF (15 mL) was added. The solution was allowed to warm up to room temperature and stirred overnight. The reaction mixture was washed with aqueous sodium hydrogen carbonate and brine. The solution was dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was separated by column chromatography on aluminium oxide (hexane/dichloromethane = 3/1 (v/v)) to give 7 as a white solid (964 mg, 79%). 7: mp 31 C; 1H NMR (300 MHz,CDCl3): 8.67 (d, 1H, J = 4.8 Hz), 8.51 (d, 1H, J = 2.1 Hz), 8.36 (d, 1H, J = 8.0 Hz), 8.31 (d, 1H, J = 8.1 Hz), 7.81 (td,1H, J = 7.7, 1.6 Hz), 7.64 (dd, 1H, J = 8.1, 2.0 Hz), 7.31-7.29 (m, 1H), 3.41 (t, 2H, J = 6.7 Hz), 2.70 (t, 2H, J = 7.6 Hz), 1.91 (quintet, 2H, J = 7.1 Hz), 1.70 (quintet, 2H, J = 7.6 Hz), 1.57-1.49 (m, 2H); 13C NMR (75 MHz, CDCl3): 156.2, 154.0,149.3, 149.2, 137.7, 136.9, 136.8, 123.5, 120.8, 120.7, 33.6,32.7, 32.5, 30.2, 27.7; MS (EI+): m/z 304 [M+]; IR (KBr,cm-1): 3067(m), 3053(m), 3011(m), 2962(m), 2943(s), 2928(s), 2866(s), 1585(s), 1574(m), 1557(s), 1460(s), 1429(s), 1392(m), 1350(w), 1304(w), 1258(m), 1230(m), 1205(m), 1190(w), 1148(w), 1092(w), 1065(w), 1042(w), 1030(m), 1013(m), 991(m), 860(s), 808(m), 785(s), 752(s), 737(m), 727(m), 640(s), 606(s); HRMS (EI+): m/z calcd for C15H1779BrN2 [M+]: 304.0575; found: 304.0577.

56100-20-0 5-Methyl-2,2′-bipyridine 11073848, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Ninomiya, Yoshikazu; Kozaki, Masatoshi; Suzuki, Shuichi; Okada, Keiji; Bulletin of the Chemical Society of Japan; vol. 87; 11; (2014); p. 1195 – 1201;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of PKS8179 (85 mg, 188 mol) and triBoc-cyclam (94 mg, 188 mol) in DCM (4 mL)was stirred at ambient temperature for 2 h and then sodium triacetoxyborohydride (120 mg, 564 mol)was added. The resulting mixture was stirred at ambient temperature overnight. Excess reagent wasquenched with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted withdichloromethane. The combined organic layers were dried over anhydrous sodium sulfate andevaporated, and the crude residue was purified by Combi-Flash (silica gel; ethyl acetate in hexane) togive PKS8181 (140 mg, 80%) as a colorless gum which turned into a fluffy solid under vacuum., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

Solid 1,3,5-triazacyclononane (16 mg, 0.12 mmol) was added to an aqueous solution of freshly prepared [Cp*Ir(H2O)3]SO4 (0.1 mmol in 5 mL). The yellow solution was stirred for 16 hours at room temperature and then taken to dryness under reduced pressure. The solid residue was taken up in 2 mL of dry methanol and the solution filtered through 0.2 mum pore size Teflon filter. Addition of 12 mL Et2O caused precipitation of a fine solid, and after taking off the pale yellow supernatant a colorless powder remained which was dried in vacuo. Yield 43 mg (78%). 1H-NMR (400 MHz, D2O): delta=3.09 (m, 6H), 2.95 (m, 6H), 1.81 (s, 15H). 13C-NMR (126 MHz, D2O): delta=88.1, 52.2, 7.8.

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sheehan, Stafford Wheeler; Hintermair, Ulrich; Thomsen, Julianne M.; Brudvig, Gary W.; Crabtree, Robert H.; US2015/21194; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.

A stirred solution of sodium 2,2-dimethyl-N,N-dichlorotaurine (35 g, 143 mmol) in 175 mL of water was treated with a solution of tetrabutylphosphonium chloride (38 g, 129 mmol) in 175 mL of water. The resulting suspension was stirred 10 min then 400 mL of ethyl acetate was added and the mixture was stirred vigorously. After separation of the layers, the aqueous layer was extracted with 2¡Á200 mL of ethyl acetate. The combined organic layers were dried over sodium sulfate and filtered. The sodium sulfate pad was washed with 2¡Á100 mL of ethyl acetate. The filtrate was concentrated to dryness and placed under high vacuum overnight (0.4 torr)to constant weight which provided 2,2-dimethyl-N,N-dichlorotaurine tetrabutylphosphonium (59.9 g, 96.6%) as a white solid, mp 118-120 C. 1H NMR (CDCL3) 3.34 (s, 2H); 2.33 (q, 8H); 1.65 (s, 6H); 1.54 (m, 16H); 0.99 (t, 12H)., 2304-30-5

The synthetic route of 2304-30-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ALCON RESEARCH, LTD.; US2009/197838; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Di-tert-butyl dicarbonate (Boc2O, 5.1 g, 23.2 mmol) in anhydrous trichloromethane (30 mL) was added dropwise to a stirred solution of TACN (2.0 g, 15.5 mmol) and triethylamine (4.7 mL, 3.1 g, 31.0 mmol) in anhydrous trichloromethane (100 mL). The resulting reaction mixture was stirred for 24 h at room temperature. Excess triethylamine was removed by washing the reaction mixture with water (3 ¡Á 50 mL) and brine (2 ¡Á 50 mL). The organic layer was collected and dried over anhydrous magnesium sulfate and then filtered. The solvent was evaporated under reduced pressure to give the crude products which were purified by chromatography over silica (EtOAc(EA)/Petroleum ether(PE), 1 : 1, v/v) as colorless oil 2Boc-TACN (1) (Rf = 0.5, EA).

4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wang, Bing; Yi, Wen-Jing; Zhang, Ji; Zhang, Qin-Fang; Xun, Miao-Miao; Yu, Xiao-Qi; Bioorganic and Medicinal Chemistry Letters; vol. 24; 7; (2014); p. 1771 – 1775;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.134030-21-0,N1,N2-Dimesitylethane-1,2-diamine,as a common compound, the synthetic route is as follows.

Preparation of 1,3-dimesityl-4,5-dihydro-imidazolium tetrafluoroborate A round bottom flask was charged with 1,2-dimesityl ethylene diamine (3.8 g, 12.8 mmol), triethyl orthoformate (15 mL) and ammonium tetrafluoroborate (1.35 g, 12.8 mmol). The reaction mixture was stirred at 120 C. for 4 hours at which time TLC indicated complete conversion. Volatiles were removed in vacuo and the product was used as prepared or it could be purified further by recrystallization from ethanol/hexanes.

134030-21-0, As the paragraph descriping shows that 134030-21-0 is playing an increasingly important role.

Reference£º
Patent; CALIFORNIA INSTITUTE OF TECHNOLOGY; GRUBBS, Robert H.; SCHOLL, Matthias; (16 pag.)US2016/237101; (2016); A9;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI